Have any questions? 706-721-6582 or cts@augusta.edu
- CA209-73L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
Clinical Trial
CA209-73L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
The purpose of this study is to evaluate th effectiveness, safety, and tolerability of adding the investigational drug, Nivolumab, to concurrent chemoradiotherapy followed by treatment with Nivolumab and Ipilimumab or Nivolumab alone, in participants with stage 3, locally advanced non-small cell lung cancer. Participants in the control group will receive concurrent chemoradiotherapy followed by treatment with Durvalumab.
Eligibility Criteria
- Inclusion: 1. Patients with locally advanced stage IIIA, IIIB, IIIC histologically-confirmed NSCLC. 2. Patients with newly diagnosed and treatment-naive, with no prior local or systemic anticancer therapy given as primary therapy for locally advanced disease. Exclusion: 1. Participants with an active, known ior suspected autoimmune disease.
RESEARCH. INNOVATION. DISCOVERY.